Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ASH Ends With Consistent Kite CAR-T Data, Some Hope For Juno

Executive Summary

Kite reported interim results for KTE-C19 from the ZUMA-1 study that showed efficacy consistent with earlier results without the deaths from neurotoxicity that have plagued Juno, but Juno’s latest CAR-T offering may carry fewer safety concerns.

You may also be interested in...



What's Gilead Getting From Kite For Nearly $12bn?

The $180 per share that Gilead's paying for CAR-T maker Kite was deemed too high by some and just right by others, but the big biotech expects a lot from its new cell therapy platform.

BLA Accepted: Novartis Inches Ahead In CAR-T Race With Kite

Novartis may very well have the first CAR-T therapy approved in the US, beating its rival Kite Pharma to the finish line, since the FDA has accepted the Swiss big pharma's BLA for priority review. Kite says it will complete its rolling BLA submission in a different indication by the end of March.

Juno Ends JCAR015 Development In ALL, Cementing Third Place CAR-T Position

Juno and partner Celgene closed the ROCKET study for JCAR015, which has been on clinical hold since November, and ended development in ALL in favor of its new and improved CD19-targeting CAR-T therapies.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

SC097825

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel